Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Heidi Steinfeldt"'
Autor:
William T. Bellamy, Alan F. List, Yazdi K. Pithavala, Francis J. Giles, Heidi Steinfeldt, Miloslav Beran, Zeev Estrov, Farhad Ravandi, Susan O'Brien, Paul Bycott, Karen W.L. Yee, Steven D. Reich, Srdan Verstovsek
Publikováno v:
Leukemia Research. 30:801-811
AG-013736 is an oral anti-angiogenesis agent with activity against a variety of receptor tyrosine kinases, including VEGFR-1, VEGFR-2, VEGFR-3, c-kit, and PDGFR-beta. A phase 2 study was conducted in patients with poor prognosis AML or MDS. Twelve pa
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d0473f597f738770f1122e20eaac3973
https://doi.org/10.1016/j.leukres.2005.10.024
https://doi.org/10.1016/j.leukres.2005.10.024
Autor:
Garth Cruickshank, John C. Vickerman, Stuart Green, J. Doran, J. Hardie, C. Wojnecki, A. Chopra, M. Chester, Steven Ford, Allah Detta, Nicholas D. James, R. Braithwaite, G. Croswell, N. Graham, Nicholas P. Lockyer, Gavin Halbert, T. M. T. Sheehan, Desire Ngoga, R. Sugar, Alan V. Boddy, Heidi Steinfeldt, Mary Elliot, Z. Ghani
Publikováno v:
Applied radiation and isotopes : including data, instrumentation and methods for use in agriculture, industry and medicine. 67(7-8)
This paper describes results to-date from a human pharmacokinetic study which began recruitment in December 2007. Results are presented for a single patient recruited in December 2007. A second patient was recruited in July 2008 but detailed data are
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::288ecaef7ad6f15846cf6064c564f8af
https://pubmed.ncbi.nlm.nih.gov/19447633
https://pubmed.ncbi.nlm.nih.gov/19447633
Autor:
Anna L. Olsen, Richard H. Wilson, Chris Jones, Patrick Johnson, Heidi Steinfeldt, Ruth Plummer, Mark R. Middleton, Hilary Calvert, Alan V. Boddy, Diane Wang, R. Dewji, L Robson, Nicola J. Curtin, Peter J. McHugh, Jeff Evans, David R. Newell, Adrian L. Harris
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 14(23)
Purpose: One mechanism of tumor resistance to cytotoxic therapy is repair of damaged DNA. Poly(ADP-ribose) polymerase (PARP)-1 is a nuclear enzyme involved in base excision repair, one of the five major repair pathways. PARP inhibitors are emerging a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f0da91b9793f020047923ccc2d6a2f50
https://pubmed.ncbi.nlm.nih.gov/19047122
https://pubmed.ncbi.nlm.nih.gov/19047122
Autor:
Glenn Liu, James L. Freddo, Steven D. Reich, Yazdi K. Pithavala, John W. Park, Roy S. Herbst, George Wilding, Merrill S. Kies, Hope S. Rugo, Heidi Steinfeldt
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 23(24)
Purpose We studied the safety, clinical activity, and pharmacokinetics (PK) of AG-013736, an oral receptor tyrosine kinase inhibitor of vascular endothelial cell growth factor, platelet-derived growth factor, and c-Kit, in patients with advanced canc
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5adf9f7a1915385e40c1b645476622f4
https://pubmed.ncbi.nlm.nih.gov/16027435
https://pubmed.ncbi.nlm.nih.gov/16027435
Autor:
Mark R. Middleton, Chris Jones, Heidi Steinfeldt, R Kaufman, Alan Hilary Calvert, J. Evans, Ruth Plummer, L Robson, S. D. Reich, Richard K. Wilson
Publikováno v:
Journal of Clinical Oncology. 23:3065-3065
3065 Background: AG-014699 inhibits poly(ADP-ribose) polymerase (PARP) is a key enzyme in DNA repair. AG-014699 sensitizes cancer cells to DNA damaging drugs such as TMZ. AG-014699 is the first PARP inhibitor to be evaluated in cancer patients. Metho
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::986dc971266c8d5fa9816e20a1606c26
https://doi.org/10.1200/jco.2005.23.16_suppl.3065
https://doi.org/10.1200/jco.2005.23.16_suppl.3065
Autor:
Paul Bycott, Alan F. List, Yazdi K. Pithavala, Francis J. Giles, Heidi Steinfeldt, William T. Bellamy, Steven D. Reich
Publikováno v:
Blood. 104:1813-1813
Background: AG-013736 is a potent and selective inhibitor of VEGF, PDGF and cKit receptor tyrosine kinases with broad preclinical activity in solid tumors and an AML model. To investigate the anti-leukemic effects of AG-013736 in patients with poor p
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b09272ec601a5e2094c3c14c66ff883f
https://doi.org/10.1182/blood.v104.11.1813.1813
https://doi.org/10.1182/blood.v104.11.1813.1813
Autor:
Merrill S. Kies, Hope S. Rugo, G. Wilding, S. D. Reich, Glenn Liu, Roy S. Herbst, John W. Park, T. M. McShane, Heidi Steinfeldt, Yazdi K. Pithavala
Publikováno v:
Journal of Clinical Oncology. 22:2503-2503
2503 Background: AG-013736 is a potent and selective inhibitor of VEGF and PDGF receptor tyrosine kinases with broad preclinical activity in xenograft models of solid tumors. Methods: The primary objective was to determine maximum tolerated dose (MTD
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::106427a02a571a960e0b23fff0efe660
https://doi.org/10.1200/jco.2004.22.90140.2503
https://doi.org/10.1200/jco.2004.22.90140.2503
Autor:
Gary R. Hudes, S. D. Reich, Oliver Bolte, Robert J. Motzer, Olivier Rixe, Ronald M. Bukowski, M.D. Michaelson, Brian I. Rini, G. Wilding, Heidi Steinfeldt
Publikováno v:
Memorial Sloan Kettering Cancer Center
4509 Background: Clear cell renal carcinoma (RCC) is characterized by inactivation of the von Hippel-Lindau tumor suppressor gene, which leads to overexpression of hypoxia-regulated genes including...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fd57cee7cb68b864e0f6174a21717c5e
https://synapse.mskcc.org/synapse/works/44868
https://synapse.mskcc.org/synapse/works/44868
